| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2020-02-26 21:40:07 UTC |
|---|
| HMDB ID | HMDB0014680 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Nortriptyline |
|---|
| Description | Nortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use). |
|---|
| Structure | CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12 InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-Delta(5,gamma)-propylamine | ChEBI | | 3-(10,11-Dihydro-5H-dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine | ChEBI | | Ateben | ChEBI | | Avantyl | ChEBI | | Aventyl | ChEBI | | Demethylamitriptyline | ChEBI | | Desmethylamitriptyline | ChEBI | | Noritren | ChEBI | | Nortriptylina | ChEBI | | Nortriptylinum | ChEBI | | Psychostyl | ChEBI | | Sensaval | ChEBI | | Nortrilen | Kegg | | 10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-delta(5,g)-propylamine | Generator | | 10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-δ(5,γ)-propylamine | Generator | | 10,11-Dihydro-N-methyl-5H-dibenzo[a,D]cycloheptene-δ(5,g)-propylamine | HMDB | | Apo nortriptyline | HMDB | | Desmethylamitriptylin | HMDB | | Gen nortriptyline | HMDB | | Lundbeck brand OF nortriptyline hydrochloride | HMDB | | Novo nortriptyline | HMDB | | Novopharm brand OF nortriptyline hydrochloride | HMDB | | Reig jofre brand OF nortriptyline hydrochloride | HMDB | | Apotex brand OF nortriptyline hydrochloride | HMDB | | Genpharm brand OF nortriptyline hydrochloride | HMDB | | Hydrochloride, nortriptyline | HMDB | | Nortriptyline hydrochloride | HMDB | | Novo-nortriptyline | HMDB | | PMS-Nortriptyline | HMDB | | Ratio nortriptyline | HMDB | | Allegron | HMDB | | Apo-nortriptyline | HMDB | | Dista brand OF nortriptyline hydrochloride | HMDB | | Gen-nortriptyline | HMDB | | Lilly brand OF nortriptyline hydrochloride | HMDB | | Nu-pharm brand OF nortriptyline hydrochloride | HMDB | | PMS Nortriptyline | HMDB | | Pamelor | HMDB | | Pharmascience brand OF nortriptyline hydrochloride | HMDB | | Desitriptyline | HMDB | | Mallinckrodt brand OF nortriptyline hydrochloride | HMDB | | Norfenazin | HMDB | | Nu nortriptyline | HMDB | | Nu pharm brand OF nortriptyline hydrochloride | HMDB | | Nu-nortriptyline | HMDB | | Paxtibi | HMDB | | Ratiopharm brand OF nortriptyline hydrochloride | HMDB | | Ratio-nortriptyline | HMDB |
|
|---|
| Chemical Formula | C19H21N |
|---|
| Average Molecular Weight | 263.3767 |
|---|
| Monoisotopic Molecular Weight | 263.167399677 |
|---|
| IUPAC Name | methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine |
|---|
| Traditional Name | nortriptyline |
|---|
| CAS Registry Number | 72-69-5 |
|---|
| SMILES | CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12 |
|---|
| InChI Identifier | InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3 |
|---|
| InChI Key | PHVGLTMQBUFIQQ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dibenzocycloheptenes. Dibenzocycloheptenes are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Dibenzocycloheptenes |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Dibenzocycloheptenes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Dibenzocycloheptene
- Secondary amine
- Secondary aliphatic amine
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Amine
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 213 - 215 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.00087 g/L | Not Available | | LogP | 4.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.95 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.9879 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.35 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1732.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 317.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 178.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 191.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 161.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 479.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 474.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 310.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1253.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 490.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1295.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 319.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 357.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 295.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 256.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Nortriptyline,1TMS,isomer #1 | CN(CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12)[Si](C)(C)C | 2529.5 | Semi standard non polar | 33892256 | | Nortriptyline,1TMS,isomer #1 | CN(CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12)[Si](C)(C)C | 2579.1 | Standard non polar | 33892256 | | Nortriptyline,1TMS,isomer #1 | CN(CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12)[Si](C)(C)C | 2942.5 | Standard polar | 33892256 | | Nortriptyline,1TBDMS,isomer #1 | CN(CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12)[Si](C)(C)C(C)(C)C | 2731.5 | Semi standard non polar | 33892256 | | Nortriptyline,1TBDMS,isomer #1 | CN(CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12)[Si](C)(C)C(C)(C)C | 2848.1 | Standard non polar | 33892256 | | Nortriptyline,1TBDMS,isomer #1 | CN(CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12)[Si](C)(C)C(C)(C)C | 3050.1 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Nortriptyline EI-B (Non-derivatized) | splash10-0006-9000000000-bb9eae4818c0402317ee | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Nortriptyline EI-B (Non-derivatized) | splash10-0006-9000000000-bb9eae4818c0402317ee | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Nortriptyline GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-9040000000-03aa30e0f3d1715d991e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Nortriptyline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Nortriptyline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | MS | Mass Spectrum (Electron Ionization) | splash10-0006-9230000000-15f73e5232a0e230f41b | 2014-09-20 | Not Available | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QTOF , positive-QTOF | splash10-05nf-5970000000-f92c7d23474b57a4ba50 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-03di-0090000000-4c40cb3ec4df8809981e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-06sl-2590000000-be2abd28b2b0f75dd8bb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-05mo-3940000000-6a454924ec75665c6175 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-05mo-3930000000-eb8141866b19782dd1e5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-00kf-4930000000-81614e655fc32d5839ce | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-00kf-4930000000-f918306a99d07f887503 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-0gdl-5930000000-d876ab376d0e9885d06d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-0gb9-5930000000-e51a246750bf8ce7e4ec | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline LC-ESI-QFT , positive-QTOF | splash10-0gbi-5930000000-c2811578219a3a7e1ccf | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline , positive-QTOF | splash10-03yi-0490000000-094e7bdb831aed030f5f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline 75V, Positive-QTOF | splash10-00kf-4930000000-fb69faeba7a357c5bc5a | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline 90V, Positive-QTOF | splash10-00kf-4930000000-76afa553a0a96ca36196 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline 30V, Positive-QTOF | splash10-06sl-2590000000-8294a4644460a638747b | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline 15V, Positive-QTOF | splash10-03di-0090000000-ff969015b0f97e8c78bc | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline 45V, Positive-QTOF | splash10-05mo-3940000000-2244b5f59802d5d17a11 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline 60V, Positive-QTOF | splash10-05mo-3930000000-ae25ca0dbf191a8decb7 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nortriptyline -1V, Positive-QTOF | splash10-05nf-5970000000-279d8674cee6125e1363 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 10V, Positive-QTOF | splash10-03e9-1090000000-0122fb1ff7e4f061277f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 20V, Positive-QTOF | splash10-01qc-3290000000-820f6bab951ae7e9352d | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 40V, Positive-QTOF | splash10-0006-6950000000-d6a7a0dcc07c2ab8c35f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 10V, Negative-QTOF | splash10-03di-0090000000-6586d2d06dd2491b85d0 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 20V, Negative-QTOF | splash10-03di-1090000000-3af72990a6e6a4c9e3ab | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 40V, Negative-QTOF | splash10-001l-4290000000-05af30a36ff956182b21 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nortriptyline 10V, Positive-QTOF | splash10-03di-0090000000-0f92e6ab1c1e69d00ae5 | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|